JP2024513244A5 - - Google Patents

Info

Publication number
JP2024513244A5
JP2024513244A5 JP2023561319A JP2023561319A JP2024513244A5 JP 2024513244 A5 JP2024513244 A5 JP 2024513244A5 JP 2023561319 A JP2023561319 A JP 2023561319A JP 2023561319 A JP2023561319 A JP 2023561319A JP 2024513244 A5 JP2024513244 A5 JP 2024513244A5
Authority
JP
Japan
Prior art keywords
sequence
seq
amino acid
substitution
acid position
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561319A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513244A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023402 external-priority patent/WO2022216653A1/en
Publication of JP2024513244A publication Critical patent/JP2024513244A/ja
Publication of JP2024513244A5 publication Critical patent/JP2024513244A5/ja
Pending legal-status Critical Current

Links

JP2023561319A 2021-04-07 2022-04-05 抗原結合タンパク質構築物および抗体およびその使用 Pending JP2024513244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171705P 2021-04-07 2021-04-07
US63/171,705 2021-04-07
PCT/US2022/023402 WO2022216653A1 (en) 2021-04-07 2022-04-05 Antigen-binding protein constructs and antibodies and uses thereof

Publications (2)

Publication Number Publication Date
JP2024513244A JP2024513244A (ja) 2024-03-22
JP2024513244A5 true JP2024513244A5 (cg-RX-API-DMAC7.html) 2025-04-15

Family

ID=81384769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561319A Pending JP2024513244A (ja) 2021-04-07 2022-04-05 抗原結合タンパク質構築物および抗体およびその使用

Country Status (10)

Country Link
US (1) US20240158493A1 (cg-RX-API-DMAC7.html)
EP (1) EP4320157A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513244A (cg-RX-API-DMAC7.html)
KR (1) KR20230165792A (cg-RX-API-DMAC7.html)
CN (1) CN117083300A (cg-RX-API-DMAC7.html)
AU (1) AU2022254042A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215265A1 (cg-RX-API-DMAC7.html)
IL (1) IL306129A (cg-RX-API-DMAC7.html)
MX (1) MX2023011919A (cg-RX-API-DMAC7.html)
WO (1) WO2022216653A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120035607A (zh) * 2022-10-12 2025-05-23 神话治疗股份有限公司 Lrrc-15结合蛋白构建体及其用途
WO2026093513A1 (en) * 2024-10-31 2026-05-07 Sotio Biotech A.S. Anti-lrrc15 antibodies and uses thereof
WO2026112478A1 (en) * 2024-11-24 2026-05-28 Mythic Therapeutics, Inc. Lrrc15-binding proteins, multispecific anti-lrrc15 x anti-tumor-associated antigen (taa) antibodies, conjugation linkers, and methods of use and production thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
NZ602220A (en) * 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
CA2871934C (en) * 2012-04-30 2023-06-13 Medimmune, Llc Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
EP3283103A4 (en) * 2015-04-15 2018-12-05 Medimmune, LLC Methods for treating clostridium difficile infection and associated disease
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
EP3383909B1 (en) * 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
JP2019501124A (ja) * 2015-11-30 2019-01-17 アッヴィ・インコーポレイテッド 抗huLRRC15抗体薬物コンジュゲート及びその使用方法
US11596699B2 (en) * 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
RS61659B1 (sr) 2016-05-17 2021-04-29 Abbvie Biotherapeutics Inc Konjugati antitelo lek anti-cmet i metode za njihovu upotrebu
US20200199247A1 (en) * 2017-06-07 2020-06-25 Silverback Therapeutics, Inc. Antibody conjugates of immune-modulatory compounds and uses thereof
WO2019084060A1 (en) * 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CN114786732A (zh) * 2019-06-06 2022-07-22 神话治疗股份有限公司 抗原结合蛋白构建体及其用途
US20220306751A1 (en) * 2019-09-13 2022-09-29 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof

Similar Documents

Publication Publication Date Title
US20210386865A1 (en) Method for selectively manufacturing antibody-drug conjugate
JP2024505577A5 (cg-RX-API-DMAC7.html)
JP6310033B2 (ja) 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
JP2019214628A (ja) セリンプロテアーゼ分子および療法
JP6534654B2 (ja) Tm4sf1結合性タンパク質およびそれを使用する方法
Fabbrini et al. Selective occlusion of tumor blood vessels by targeted delivery of an antibody‐photosensitizer conjugate
US20180243435A1 (en) Anti-dll3 antibody drug conjugates and methods of use
RS63918B1 (sr) Antitelo-lek konjugati i njihova upotreba u tretmanu kancera
CN111712520A (zh) 磷脂酰肌醇聚糖3抗体及其偶联物
CN107007840A (zh) 抗‑cd19类美登素免疫缀合物抗体在治疗b‑细胞恶性肿瘤症状中的用途
JP2022543771A5 (cg-RX-API-DMAC7.html)
CN111315779A (zh) 抗-cd3抗体及包含其的用于癌症治疗的药物组合物
CN112135843A (zh) 抗sez6抗体药物缀合物和使用方法
CA3196218A1 (en) Means and methods for producing antibody-linker conjugates
AU2016378744A1 (en) Novel anti-UPK1B antibodies and methods of use
AU2017214685B2 (en) EGFL6 specific monoclonal antibodies and methods of their use
JP2022534808A5 (cg-RX-API-DMAC7.html)
JP2020501513A (ja) 治療用多標的コンストラクトおよびその使用
Sun et al. hIMB1636-MMAE, a novel TROP2-targeting antibody-drug conjugate exerting potent antitumor efficacy in pancreatic cancer
AU2017261369A1 (en) Novel anti-TNFRSF21 antibodies and methods of use
CN110075315B (zh) 一种抗体偶联物及其制备方法和应用
JP2024523290A5 (cg-RX-API-DMAC7.html)
JP2022551844A5 (cg-RX-API-DMAC7.html)
JP2025509338A (ja) Ror1標的結合分子とその使用
JP2019536802A (ja) 毛様体神経栄養因子受容体リガンド結合剤およびその使用方法